Salience Labs Closed Series A Round Led by Applied Ventures and ICM HPQC Fund
7.2.2025 09:14:00 CET | Business Wire | Press release
Appointment of Dr. William Jeffrey to the Board and Bonnie Tomei as CFO
Salience Labs Limited, a leader in photonic solutions targeting connectivity for AI datacenter infrastructure, today announced the successful close of $30 million in Series A financing led by ICM HPQC Fund and Applied Ventures, LLC, the venture capital arm of Applied Materials, Inc., to further the development of its optical switches for large scale AI connectivity. Applied Ventures and ICM HPQC Fund are joined by Strategic Investment Fund, Braavos, and continued participation from existing investors Oxford Sciences Enterprises, Cambridge Innovation Capital, and leaders from the global semiconductor industry including Silicon Catalyst and Jalal Bagherli.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250207290130/en/
Image by Shabbir Bashar
“What our customers want is a photonic switch to connect their AI clusters that is compatible with existing infrastructure while delivering high bandwidth, low latency and significant power savings. The completion of this round will further our development and help us bring our product to customers to enable not just the savings, but large cluster connectivity,” said Vaysh Kewada, Co-founder and CEO of Salience Labs. “We are also excited to be working closely with our strategic investors who are industry leaders to advance our go-to market schedule.”
“Silicon photonics is a promising technology to deliver significant advancements in energy-efficient performance for AI data centers,” said Anand Kamannavar, Vice President and Global Head of Applied Ventures. “Salience's optical switch solution has the potential to enable a new generation of interconnect network architectures for faster and more efficient AI systems.”
“Salience Labs has done a tremendous job in developing a portfolio of innovative silicon photonics products that addresses critical needs in data center and AI infrastructure market,” said Dr. Jalal Bagherli, investor of Salience Labs and former CEO of Dialog Semiconductor that was acquired by Renesas. “Their customer focused approach in addition to the technology that are based on over a decade of research makes Salience Labs a clear leader to win in this enormous market.”
“Salience Lab’s optical switches will enable unprecedented bandwidth and scalability for the next generation of AI and high-performance data centers. By leveraging light, they will unlock the full capability of modern servers while decreasing power consumption and cost. ICM HPQC is excited to work with Vaysh and the Salience team as lead of the Series A raise,” said Dr. William Jeffrey, Chairman of the technical advisory committee on the ICM HPQC Fund and newly appointed Board Member of Salience Labs.
Appointment of Dr. William Jeffrey as new Board Member
In conjunction with the closing of the Series A financing, Salience Labs is appointing Dr. Jeffrey to the Board of Directors, where he joins Jack Edmondson, Chief Investment Officer of Oxford Sciences Enterprises, and Daniel Armbrust, co-founder of Silicon Catalyst, CEO of the SEMATECH semiconductor consortium and appointee to the Industrial Advisory Committee, which advises the Department of Commerce on the R&D strategy for the CHIPS Act.
Dr. Jeffrey is an astronomer with a career spanning the Executive Office of the President of the United States, to leading HRL (known for its groundbreaking innovations such as the invention of the laser, integrated circuits and liquid crystal displays), to being the Director of the National Institute of Standards and Technology, an institution boasting three Nobel prize laureates and ties to a dozen more, and he served as the CEO of SRI International. Dr. Jeffrey earned a Bachelor of Science in physics from the Massachusetts Institute of Technology and a Ph.D. in astronomy from Harvard University.
Appointment of Bonnie Tomei as Chief Financial Officer
Salience Labs is also announcing its appointment of Bonnie Tomei, a certified public accountant and an industry veteran located in Silicon Valley, California, as Chief Financial Officer.
“With over 20 years of experience including initial public offerings, de-SPAC and a strong business operations background, Ms. Tomei will be a key member of the executive team to realize our strategic and operational objectives, including expanding to the U.S. to serve our key customers,” said Ms. Kewada.
About Salience Labs
Salience Labs Limited is a leader in photonic solutions targeting connectivity for AI datacenter infrastructure. Founded in 2021 and backed by over a decade of research from the University of Oxford in the UK and University of Münster in Germany, Salience’s innovative developments in photonic switching technology enable high-speed, ultra-low latency networking fabrics that remove infrastructure bottlenecks for AI workloads. Learn more at http://www.saliencelabs.ai
View source version on businesswire.com: https://www.businesswire.com/news/home/20250207290130/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press release
The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypesThe frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide added to R-CHOP for previously untreated DLBCLThe data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet* Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating t
Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom